NCCN Adjuvant Therapy for Breast Cancer Task Force Members *Robert W. Carlson, MD / Chair#† ¶¶ Stanford Hospital and Clinics Donald A. Berry, PhD†† The University of Texas M. D. Anderson Cancer Center *Elizabeth Brown, MD National Comprehensive
Search Results
Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force
Jeffrey K. Belkora, David W. Hutton, Dan H. Moore, and Laura A. Siminoff
P atients with breast cancer who are at relatively low risk for recurrence or mortality after local therapy (surgery with or without radiation) face a “grey zone” decision about whether to undergo adjuvant therapy. 1 The choice of therapy
Katherine Van Loon and Alan P. Venook
Adjuvant therapy for colon cancer evolved in an additive fashion. In the 1980s, 5-fluorouracil (5-FU) administered as a daily bolus regimen made the first positive impact of any therapy on colon cancer survival. 1 The ensuing decade of research
Michael S. Sabel and Vernon K. Sondak
: 3635 – 3648 . 2 Dickler MN Coit DG Myers ML . Adjuvant therapy of malignant melanoma . Surg Oncol Clin N Am 1997 ; 6 : 793 – 812 . 3 Pfeffer LM Dinarello CA Herberman RB . Biological properties of recombinant alpha
Jashodeep Datta, Matthew T. McMillan, Eric K. Shang, Ronac Mamtani, Russell S. Lewis Jr, Rachel R. Kelz, Ursina Teitelbaum, John P. Plastaras, Jeffrey A. Drebin, Douglas L. Fraker, Giorgos C. Karakousis, and Robert E. Roses
incorporated into practice guidelines for GA management in the United States. Subsequently, several retrospective population-based studies have reaffirmed the benefit of adjuvant therapy in patients undergoing curative-intent gastrectomy. 7 – 9 Based on these
Scott M. Schuetze and Michael E. Ray
1995 ; 72 : 469 – 475 . 24 Zalupski MM Ryan JR Hussein ME Balker LH . Defining the role of adjuvant chemotherapy for patients with soft tissue sarcoma of the extremities . In: Salmon SE , ed. Adjuvant Therapy of Cancer VII. Philadelphia
Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh
Although perioperative chemotherapy and postoperative chemoradiation are the 2 evidence-based options for gastric cancer, 4 , 6 ongoing multicenter trials are investigating whether strategies that move most or all of the adjuvant therapy to the
Jacqueline Jonklaas
Normal thyrocytes and thyroid cancer cells are characterized by possession of a sodium iodide symporter. Radioiodine administration is a unique and powerful means of treating differentiated thyroid cancer because of the ability of thyroid cancer cells to concentrate beta-emitting radiolabeled iodine. Several manipulations, such as iodine depletion and thyroid hormone-stimulating hormone elevation, are used to enhance uptake of radiolabeled iodine by tumor cells. Adjuvant radioiodine therapy, given to patients without evidence of residual disease, enhances the sensitivity of subsequent surveillance and may decrease recurrence rates and mortality. However, its exact role in the management of low-risk patients merits further investigation. In contrast, radioactive iodine therapy used in patients with residual or metastatic disease clearly improves outcomes. Several studies show decreased recurrence and mortality rates in patients treated with radioiodine compared with those not receiving radioactive iodine. Adverse events from radioiodine therapy include salivary gland dysfunction, bone marrow suppression, and reproductive disturbances. Side effects of radioiodine therapy are generally greater when higher activities of radioiodine are used and may be transient or permanent. Secondary malignancies also may occur after radioiodine therapy. These side effects must be weighed against potential benefits, especially when radioactive iodine is used as adjuvant therapy. Stimulation of the expression of the sodium iodide symporter, or its introduction de novo into nonthyroid cells, is promising in treating poorly differentiated thyroid cancer and nonthyroid malignancies, respectively.
John Khoury, David Macari, Daniel Ezekwudo, Ayoda Werede, and Ishmael A. Jaiyesimi
Background: There is controversy surrounding the benefit of adjuvant therapy for patients with pT2N0, stage IB gastric adenocarcinoma following surgical resection. Methods: Patients with T2N0 gastric adenocarcinoma (tumor invasion into the
Leslie A. Fecher and Keith T. Flaherty
alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 . J Clin Oncol 1996 ; 14 : 7 – 17 . 11 Kirkwood J Manola J Ibrahim J . A pooled analysis of eastern cooperative
